AVTE Aerovate Therapeutics Inc

Price (delayed)

$1.84

Market cap

$53.01M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.04

Enterprise value

$44.66M

Highlights
AVTE's debt is down by 20% YoY but it is up by 15% from the previous quarter
The net income has declined by 44% year-on-year and by 9% since the previous quarter
The quick ratio has contracted by 43% YoY and by 8% from the previous quarter

Key stats

What are the main financial stats of AVTE
Market
Shares outstanding
28.81M
Market cap
$53.01M
Enterprise value
$44.66M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.56
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$82.13M
EBITDA
-$82.03M
Free cash flow
-$69.15M
Per share
EPS
-$3.04
Free cash flow per share
-$2.49
Book value per share
$3.26
Revenue per share
$0
TBVPS
$3.84
Balance sheet
Total assets
$106.82M
Total liabilities
$15.92M
Debt
$774,000
Equity
$90.9M
Working capital
$87.72M
Liquidity
Debt to equity
0.01
Current ratio
6.65
Quick ratio
6.4
Net debt/EBITDA
0.1
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-61.9%
Return on equity
-70.2%
Return on invested capital
-94.6%
Return on capital employed
-90%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AVTE stock price

How has the Aerovate Therapeutics stock price performed over time
Intraday
3.37%
1 week
-3.16%
1 month
17.95%
1 year
-89.17%
YTD
-91.87%
QTD
10.84%

Financial performance

How have Aerovate Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$88.39M
Net income
-$82.19M
Gross margin
N/A
Net margin
N/A
AVTE's operating income is down by 48% year-on-year and by 9% since the previous quarter
The net income has declined by 44% year-on-year and by 9% since the previous quarter

Growth

What is Aerovate Therapeutics's growth rate over time

Valuation

What is Aerovate Therapeutics stock price valuation
P/E
N/A
P/B
0.56
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
AVTE's EPS is down by 30% year-on-year and by 6% since the previous quarter
The price to book (P/B) is 89% less than the last 4 quarters average of 5.2
The company's equity fell by 20% YoY and by 17% QoQ

Efficiency

How efficient is Aerovate Therapeutics business performance
The company's return on invested capital has shrunk by 82% YoY and by 10% QoQ
The return on equity has dropped by 63% year-on-year and by 14% since the previous quarter
The return on assets has dropped by 52% year-on-year and by 12% since the previous quarter

Dividends

What is AVTE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVTE.

Financial health

How did Aerovate Therapeutics financials performed over time
The quick ratio has contracted by 43% YoY and by 8% from the previous quarter
The total liabilities has increased by 41% year-on-year but it has declined by 11% since the previous quarter
AVTE's debt is 99% less than its equity
AVTE's debt is down by 20% YoY but it is up by 15% from the previous quarter
The company's equity fell by 20% YoY and by 17% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.